Introduction
Pseudomonas aeruginosa is associated with serious infections and significant mortality, especially in patients with risk factors such as pneumonia, advanced age, immunosuppression or other serious underlying disease. Delays in effective treatment, including inappropriate empirical therapy, are associated with further increases in patient morbidity and mortality. 1, 2 Moreover, even antimicrobials deemed 'appropriate' based on susceptibility testing may be less effective when MICs are elevated, as is often the case for P. aeruginosa, as this reduces the likelihood of achieving optimal pharmacokinetic/pharmacodynamic (PK/PD) targets in patients. This, in turn, leads to reduced antimicrobial activity and worse clinical outcomes. 3 Such challenges along with rising multidrug resistance 4 -6 and limited alternatives have increased the use of antibiotic combinations and previously abandoned agents, such as colistin (polymyxin E). The ability to optimize antimicrobial PDs in practice by detecting and responding to changes in antimicrobial activity (e.g. MICs) is essential to conserving the effectiveness of existing therapies. Standard surveillance indices such as MIC 50 and MIC 90 are efficient but relatively crude indicators of susceptibility, which may not detect less obvious but significant changes in MIC distributions.
Our goal was to study antimicrobial activity over time using integrated PK/PD analyses of cefepime, meropenem, piperacillin/tazobactam, ciprofloxacin, aminoglycosides (amikacin and gentamicin) and colistin against clinical isolates of P. aeruginosa causing infections in Canadian hospitals from January 2007 to June 2012 inclusive.
Materials and methods
Monte Carlo simulation methods in SYSTAT w (V12) were used to construct cohorts of 5000 study subjects with normally distributed body weights (70.0+9.9 kg, range 45-95 kg) and uniformly distributed CL CR (60-120 mL/min/1.73 m 2 ). Empirical antipseudomonal monotherapies were studied at the standard and highest recommended doses, respectively, of cefepime [2 g intravenously (iv) twice daily, 2 g iv three-times daily], meropenem (1 g iv three-times daily, 2 g iv three-times daily), piperacillin/tazobactam (3.375 g iv four-times daily, 4.5 g iv four-times daily), ciprofloxacin (400 mg iv twice daily, 400 mg iv three-times daily), amikacin (20 mg/kg iv once daily), gentamicin (7 mg/kg iv once daily) and colistin (5 mg/kg/day iv to a maximum 300 mg, colistin base activity). The standard infusions were 0.5 h. Alternative dosing regimens used in practice, such as 500 mg iv four-times daily for meropenem and prolonged infusions over 3 or 4 h for the b-lactams, were also tested. 7, 8 The Monte Carlo simulations used PK data from published population PK models, in order to construct individual plasma concentration profiles for each antimicrobial dosing regimen in each of the 5000 simulated subjects. Population PK models with sufficient sample size and representative of the PK parameters and variability in patients with infections were selected. The models for cefepime 9 and ciprofloxacin 10 were developed in patients with predominantly lower respiratory tract, skin and soft tissue or bloodstream infections, whereas meropenem 11 was studied in intra-abdominal infection, community-acquired pneumonia or ventilatorassociated pneumonia and piperacillin/tazobactam was studied in intra-abdominal infections. 12 The models for amikacin 13 and gentamicin 14 were derived in febrile, severely neutropenic patients and hospitalized patients receiving antimicrobial therapy, respectively. The PK data for colistin were obtained from the most robust population PK study to date, developed by Garonzik et al. 15 in 105 critically ill patients. Hence, our findings for colistin are applicable to its use in that population, and not comparable to the results for the other antimicrobials tested.
The Monte Carlo simulations incorporated data from population PK models that characterized the sources and correlates of variability in antimicrobial concentrations. Covariate relationships, e.g. between antimicrobial clearance and CL CR or between antimicrobial volume of distribution and body weight, were used to generate individual PK parameters and concentration profiles for each of the 5000 simulated subjects based on their individual CL CR and body weight. For example, ciprofloxacin clearance (L/h) was determined from [(0.0014 ×CL CR + 0.167)×body weight], developed by Forrest et al. 10 Next, the required concentration data were generated including the maximum concentration (C max , mg/L) for cefepime, meropenem and piperacillin/tazobactam and the area under the concentration-time curve (AUC 24 , mg/L×h) for ciprofloxacin, amikacin and gentamicin. The latter was calculated for colistin by determining the average total steady-state concentration (C ss,ave , mg/L) from [daily dose/(1.5×CL CR + 30)] and multiplying by 24. 15 Concentration data were converted to free ( f ) concentrations according to 0.85+0.02 for cefepime, 0.93+0.02 for meropenem, 0.75+0.02 for piperacillin/tazobactam, 0.70+0.02 for ciprofloxacin and 0.90+0.02 for amikacin and gentamicin. All generated antimicrobial PK and concentration data were carefully examined for appropriateness.
Finally, the Monte Carlo simulations incorporated relevant profiles of P. aeruginosa infections in hospitalized patients using CANWARD pathogen prevalence and MIC data (broth microdilution) from January 2007 to June 2012 inclusive. The relevant PD indices were calculated and clinical targets were selected including % f T .MIC ≥ 50% for cefepime, meropenem and piperacillin/tazobactam, f AUC/MIC ≥90 for ciprofloxacin, amikacin and gentamicin, 16 and total AUC/MIC ≥60 for colistin. The latter, also described by Garonzik et al., 15 was selected based on in vitro and animal infection models of P. aeruginosa where 1 and 2 log 10 kill were associated with f AUC/MIC values of 12 -27 and 28-46, respectively. 17, 18 Although the protein binding of colistin has not been well described in humans, free fractions of 45% have been reported in animal models. 19 Accordingly, a total AUC/MIC of 60 would equate to an f AUC/MIC of 27. The probability of target attainment (PTA) for each antimicrobial and dosing regimen was calculated for each MIC as the proportion of 5000 simulated subjects that achieved the PD target. The PD target attainment against P. aeruginosa was then determined by multiplying the PTA at each MIC by the fraction of isolates at that MIC and summing the values. A subset analysis of antimicrobial PDs against P. aeruginosa causing infections in Canadian intensive care units (ICUs) was also conducted. Trends in PTA over time were assessed using Pearson correlation (PC) or Spearman correlation (SC) analyses. Changes in MIC 50 or MIC 90 by more than one dilution were considered significant.
Results
As shown in Table 1 , 2126 P. aeruginosa isolates were identified during the study period. MIC data were not available for cefepime in 2010. Antimicrobial PK and concentration data generated by Monte Carlo simulation are shown in Table 2 . The proportions of 5000 simulated subjects achieving target (PTA) with antimicrobials at the highest recommended doses are displayed in Figure 1 , whereas data for other dosing regimens are detailed in Table 3 . As demonstrated for the former, there were no significant trends in overall PTA over time for cefepime (0.93-1. Zelenitsky et al.
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Discussion P. aeruginosa is a significant nosocomial pathogen associated with high patient morbidity and mortality. Our study examined the comparative empirical activity of antipseudomonal monotherapies over time. It also demonstrated the value of integrated PK/PD analyses to identify changes in antimicrobial activity not detected by simply assessing MIC indices. There were no significant trends in overall PTA for cefepime, meropenem or piperacillin/tazobactam. This is consistent with a study by Master et al., 5 which analysed resistance rates in almost 1 million P. aeruginosa isolates collected by microbiology laboratories in the USA from 1997 to 2009. They found that resistance rates changed by ,5% for cefepime, ceftazidime, imipenem and piperacillin/tazobactam. In our study, cefepime and meropenem were the most active against clinical isolates of P. aeruginosa causing infections in Canadian hospitals, followed by piperacillin/tazobactam. Importantly, the highest recommended doses of cefepime and meropenem were required to consistently achieve a % f T .MIC ≥50% in at least 90% of cases. Depending on the dosing regimen, prolonged 3 h infusions of cefepime and meropenem only improved the PTA by up to 0.07. Standard infusions of piperacillin/tazobactam had relatively poor PD activity against P. aeruginosa (0.69 -0.79 PTA), whereas 3 h infusions improved the PTA by an additional 0.13 -0.18. Only the most aggressive piperacillin/tazobactam dose (i.e. prolonged 3 h infusions of 4.5 g four-times daily) was able to consistently attain a % f T .MIC ≥50% in at least 90% of cases.
Ciprofloxacin also showed relatively poor and variable PD activity 5 who found that resistance rates for ciprofloxacin increased from 20% in 1997, peaked at 32% in 2002 and then declined to 25% in 2009. PK/PD studies such as ours provide important clinical translations of descriptive MIC data by quantifying the effects of changing MICs on the predicted PD target attainment in patients. Such analyses are sensitive to more subtle shifts in MIC distributions, which may not be evident in MIC 50 , MIC 90 or percentage susceptible data. In some cases, the susceptibility rates are discordant with effective target attainment. In our study, the activity of ciprofloxacin was significantly overestimated by the percentage susceptible (MIC ≤1 mg/L as per CLSI) compared with the probability of achieving an f AUC/MIC ≥90 in patients. Although 82% of isolates were considered susceptible in 2012, an effective PD 
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Data shown for the highest recommended doses and standard infusions of 0.5 h.
Antimicrobial pharmacodynamics against P. aeruginosa i69 JAC target was reached in only 64% of simulated subjects (0.64 PTA). Such observations support a re-evaluation of the current susceptible MIC breakpoint, which may be incongruent with providing 'effective therapy' with ciprofloxacin at recommended doses.
Our study found notable improvements in the PTA for aminoglycosides, with dramatic increases between 2010 and 2011. These results are consistent with a study by Ababneh et al., 20 which monitored aminoglycoside use and resistance rates in 29 medical centres in the USA between 2002 and 2009. They found that while aminoglycoside use declined by 41%, the rate of gentamicin-resistant P. aeruginosa fell by 48%. 20 In our study, significant increases in the PTA for both amikacin and gentamicin were accompanied by changes in MIC indices of gentamicin only. Similar to ciprofloxacin, there were significant discrepancies between the percentage susceptible to amikacin (MIC ≤16 mg/L as per CLSI), which was consistently .90%, and the probability of achieving PD targets, which ranged from 0.21 to 0.55. In addition, as aminoglycoside activity increased, there was a concurrent rise in the PTA for colistin. The PTA for colistin, as modelled in critically ill patients, however, remained low at 0.20, which is consistent with other findings and recommendations for its use in combination therapy. 15 Finally, our analyses of P. aeruginosa causing infections in Canadian ICUs revealed a steady decline in piperacillin/tazobactam activity over time. This early observation warrants ongoing surveillance to characterize and react to significant changes in piperacillin/tazobactam therapy for the most seriously ill patients. Interestingly, there was a decrease in the percentage susceptible using the new CLSI breakpoint of ≤16 mg/L (i.e. from 82% in 2008 to 67% in 2011), which was not detected using the previous breakpoint of ≤64 mg/L (i.e. from 93% in 2008 to 90% in 2011). As discussed previously, ciprofloxacin and amikacin may also benefit from a change to MIC breakpoints that better reflect the ability to achieve PD targets in patients.
Our findings could also be relevant in examining the role of combination therapy for serious infections, such as those caused by P. aeruginosa. PD activity and target attainment may be entirely overlooked by simply comparing the use of one versus two 'susceptible' agents. This is particularly relevant when antimicrobial PD activity and effectiveness are compromised by the relatively high, yet still susceptible, MICs for pathogens such as P. aeruginosa. Our results suggest that cefepime and meropenem could achieve PD targets in most cases. Alternatively, piperacillin/tazobactam (except at the most aggressive dose) and ciprofloxacin would reach targets in substantially fewer cases and may benefit from combination therapy to achieve adequate cumulative activity. Although the PD activity for amikacin, gentamicin and colistin increased significantly over time, the probability of achieving PD targets remained too low for reliable monotherapy.
Monte Carlo simulations and findings based on simulated study subjects are associated with important limitations. Our PD analyses were based on simulated antimicrobial concentrations derived from population PK models. However, the judicious selection of population PK models with PK data described by covariate relationships allows investigators to use Monte Carlo simulations to generate individualized PK and concentration data for various antimicrobials and dosing regimens in a constant cohort of study subjects. As discussed previously, our study of colistin was based on a population PK model developed in critically ill patients and unlike the other antimicrobials Zelenitsky et al.
i70 tested, the findings of PD target attainment for colistin are specific to the ICU setting. Our analyses included only 5 years of data from 2007 to 2011. Due to the significant changes in the PTA for gentamicin and colistin, an additional 6 month assessment in 2012 was performed to determine whether these trends were sustained. Ongoing surveillance would strengthen the trend analyses and confirm the more recent observations. Similarly, our study of PD activity against P. aeruginosa isolated from ICUs was conducted on relatively small numbers of 67-120 isolates per year and would benefit from further surveillance.
In conclusion, based on integrated PK/PD analyses, the overall activity of cefepime, meropenem and piperacillin/tazobactam against P. aeruginosa was stable from 2007 to 2012. The PD activity was variable and unreliable for ciprofloxacin and improved significantly over time for the aminoglycosides and colistin. There was a progressive reduction in the PD activity of piperacillin/tazobactam against ICU isolates, which was not detected by simply assessing MIC indices. 
